Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 381 participants.

Also called NCT02620163

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 381 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02620163
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02620163. Randomized; double masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2016-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
Condition
Hypertension
Intervention (Drug)
telmisartan/amlodipine 40/5mg
Intervention (Drug)
YH22162 40/5/12.5 mg
Intervention (Drug)
telmisartan/amlodipine 80/5mg
Intervention (Drug)
YH22162 80/5/25 mg
Intervention (Drug)
telmisartan/amlodipine 40/5mg placebo
Intervention (Drug)
YH22162 40/5/12.5 mg placebo
Intervention (Drug)
telmisartan/amlodipine 80/5mg placebo
Intervention (Drug)
YH22162 80/5/25 mg placebo
Lead sponsor
Yuhan Corporation (class: industry)

Record details

Record id
cardio:ct-nct02620163
Content hash
18df5e9c80975a9100651590659c4f4f8f26764c65f9f5275881fc3bb7350ba7